



PRESS RELEASE

PledPharma AB
Stockholm October 31, 2019

Trading in PledPharma's shares commences today on the Nasdaq Stockholm main market

Stockholm, October 31, 2019. PledPharma AB (publ) announces today the commencement of trading in the company's shares on Nasdaq Stockholm's main market.

"I am very happy and proud that we are now moving up to Nasdaq Stockholm's main market. The listing is an important milestone for PledPharma that can both help create further interest from a broader investor base and reflect the maturity of our business and our global ambitions," said Nicklas Westerholm, CEO of PledPharma.

The shares will be traded on the Nasdaq Stockholm main market under the same ticker (PLED) and ISIN-code (SE0003815604). There is no fund raising or new share issue in connection with the list change, and shareholders in PledPharma do not need to take any actions.

Pareto Securities AB and Advokatfirman Lindahl KB are PledPharma's financial and legal advisers respectively, in connection with the listing.

For further information, please contact:

Nicklas Westerholm, CEO
Tel. +46 (0)73 354 20 62
nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO
Tel. +46 (0)72 231 68 00
Yilmaz.mahshid@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project **PledOx**[®] is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate **Aladote**[®] is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote[®] has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <http://www.pledpharma.com/>

The information was submitted for publication, through the agency of the contact persons set out above, at 2019-10-31 08:00 CEST.